🇺🇸 FDA
Pipeline program

Tridecanoic Acid

3027-16-SMC

Phase 2 small_molecule active

Quick answer

Tridecanoic Acid for Rett Syndrome is a Phase 2 program (small_molecule) at Ultragenyx Pharmaceutical with 1 ClinicalTrials.gov record(s).

Program details

Company
Ultragenyx Pharmaceutical
Indication
Rett Syndrome
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials